**ARC Journal of Dermatology**
*Volume 8, Issue 2, 2025, PP 36-47*
*ISSN No. (Online) 2456-0022*
*DOI: https://doi.org/10.20431/2456-0022.0802004*
*www.arcjournals.org*

# Targeting Thromboinflammation in Purpura Fulminans: Novel Therapeutic Avenues in Critical Care

**Grace Herrick[1], Eliza Skemp[2], Kelly Frasier[3*], Darianne Zimmer[4], Haily Fritts[5]**
**Julia Vinagolu-Baur[6], Mahnoor Mukarram[2], Alexander Mazzorana[1]**

*[1]Alabama College of Osteopathic Medicine, Dothan, AL*
*[2]Midwestern University Arizona College of Osteopathic Medicine, Glendale, AZ*
*[3]Northwell Health, New Hyde Park, NY*
*[4]University of California, Riverside School of Medicine, Riverside, CA*
*[5]Idaho College of Osteopathic Medicine, Meridian, ID*
*[6]SUNY Upstate Medical University, Syracuse, NY*

Received: 04 January 2025 Accepted: 03 February 2025 Published: 19 February 2025

***Corresponding Author:** ***Kelly Frasier,*** *Department of Dermatology, Northwell Health, New Hyde Park, NY*

## Abstract

*Purpura fulminans is a severe thromboinflammatory disorder characterized by widespread microvascular thrombosis and hemorrhagic infarction of the skin, often associated with sepsis or disseminated intravascular coagulation. Current treatment strategies focus on supportive care, anticoagulation, and addressing underlying infections or triggers. Despite these efforts, morbidity and mortality rates remain high, necessitating the exploration of novel therapeutic avenues. Recent research has underscored the pathophysiological mechanisms underlying thromboinflammation in purpura fulminans, highlighting the roles of the innate immune response, endothelial dysfunction, and dysregulated coagulation pathways. Targeted therapies, such as inhibitors of complement activation, toll-like receptors, and pro-inflammatory cytokines, show promise in mitigating the thromboinflammatory cascade. Additionally, advancements in the modulation of neutrophil extracellular traps (NETs) and the use of antithrombotic agents with anti-inflammatory properties are emerging as potential strategies. Future research should aim to translate these findings into clinical practice through well-designed trials, focusing on personalized medicine approaches to optimize outcomes for critically ill patients with purpura fulminans. Continued exploration of the molecular mechanisms involved and the development of biomarkers for early diagnosis and treatment response will be crucial in advancing therapeutic interventions in this challenging condition.*

## 1. Introduction

Purpura fulminans (PF) is a rare but life-threatening thromboinflammatory condition characterized by widespread microvascular thrombosis and hemorrhagic infarction of the skin. This condition presents with sudden and extensive purpuric skin lesions, often heralding severe systemic symptoms [1]. Despite aggressive interventions, mortality remains exceptionally high, approaching 90% in the most severe cases [2]. The pathogenesis of PF is complex, involving a delicate balance between inflammation and coagulation that leads to tissue ischemia and necrosis [1]. Often triggered by bacterial infections, particularly meningococcal sepsis, PF rapidly progresses to disseminated intravascular coagulation (DIC), multiorgan failure, and skin necrosis. Survivors frequently face significant long-term morbidity, including amputations due to extensive tissue loss [3]. Prompt recognition and urgent intervention are critical to mitigating the high morbidity and mortality associated with this condition. Clinically, purpura fulminans manifests with the abrupt onset of purpuric skin lesions that rapidly evolve into necrotic areas, predominantly affecting extremities and pressure points [1]. The early symptoms include fever and malaise, which rapidly give way to signs of systemic infection, such as multi-organ failure, hematuria, oliguria,

and acute respiratory distress [1]. The clinical presentation of PF overlaps with other critical conditions like meningococcemia, severe sepsis, and vasculitic syndromes, making early and accurate diagnosis a significant challenge. Delays in diagnosis and treatment can result in catastrophic outcomes underscoring the need for heightened clinical suspicion and timely therapeutic intervention.

Purpura fulminans is commonly associated with bacterial infections, such as *Neisseria meningitidis, Streptococcus pneumoniae,* and *Haemophilus influenzae,* particularly in cases of DIC [4]. This association with sepsis underscores the critical interplay between coagulation system dysregulation triggered by systemic infection. Patients with PF may be acutely ill with a fever, hypotensive, and experience hemorrhages from multiple sites, due to widespread microvascular thrombosis and subsequent hemorrhagic infarction [1]. This dysregulation of the coagulation cascade results in both thrombosis and bleeding, further compounding the severity of PF. Aside from infections, PF can be triggered by trauma, immune disorders, and inherited deficiencies in protein C, protein S, or antithrombin III [1]. Immediate recognition and management are essential for patient survival, given the rapid progression and severity of this condition. Current treatment strategies for purpura fulminans are multifaceted, focusing on supportive care, managing the underlying cause, and addressing the coagulopathy to prevent end-organ damage [1]. Supportive care includes fluid resuscitation, hemodynamic support and organ support, and in the case of an infectious trigger, appropriate antibiotics [1]. In cases of DIC, anticoagulation therapies such as heparin or warfarin are employed [1]. Severe cases may require plasmapheresis, fresh frozen plasma, or protein C concentrates to correct underlying coagulopathies. Early surgical intervention to debride necrotic tissue is often necessary to prevent further complications. Despite these interventions, patient outcomes remain poor, highlighting the urgent need for novel therapeutic approaches. Recent advances in understanding the pathophysiology of PF hav opened the door to targeted therapies aimed at modulating the inflammatory and coagulation pathways. Emerging treatments, including immunomodulators, targeted anticoagulants, and regenerative therapies hold promise for improving outcomes in this devastating condition. mortality and morbidity. This review explores emerging therapeutic strategies in the management of PF discussing the pathophysiology of purpura fulminans, current treatments, and potential novel therapies that may lead to better patient outcomes.

## 2. DISCUSSION

### 2.1. Clinical Presentation and Diagnosis

Purpura fulminans is characterized by a distinct and rapidly progressing clinical presentation that necessitates prompt recognition for timely intervention. The initial presentation typically involves erythema, which quickly advances to blue-black hemorrhagic skin necrosis. Without swift treatment, systemic involvement, including DIC and multi-organ failure, can ensue, making PF a life-threatening condition. Patients often present with widespread purpuric lesions that rapidly coalesce, evolving from petechiae into larger areas of ecchymosis and hemorrhagic infarctions. As PF advances, affected areas of purpura undergo necrosis, resulting in blackened, non-viable skin. This necrotic tissue often leads to complete loss of sensation and extensive tissue damage, frequently requiring surgical intervention [1]. Systemic symptoms such as fever, hypotension, and progression to DIC, are common, and the condition carries a mortality rate of up to 50%, rising to 60% for distal lesions and as high as 90% for truncal and widespread lesions [5]. Early and accurate recognition is essential, as delays significantly increase the risk of severe systemic complications and mortality.

Early recognition and differentiation of purpura fulminans from other dermatologic and systemic conditions are crucial for effective treatment. The rapid onset and progression of purpuric lesions, along with signs of systemic involvement, serve as key distinguishing features. Various conditions, such as Henoch-Schonlein purpura, can present with similar purpuric lesions but seldom progress to necrosis, underscoring the importance of differentiating PF from other mimicking conditions. Although a skin biopsy can provide a definitive diagnosis, the process may delay diagnosis by up to a week, potentially resulting in a detrimental delay in initiating treatment [4]. Thus, clinical suspicion should remain high when patients present with characteristic lesions and systemic signs of coagulopathy.

Diagnosis of purpura fulminans is supported by laboratory findings, histopathology, and imaging

studies. Essential laboratory evaluations include a complete blood count (CBC), coagulation profile (prothrombin time, activated partial thromboplastin time, fibrinogen), D-dimer levels, blood cultures, and assessments of organ function (renal and liver panels). A skin biopsy from the periphery of a purpuric lesion can confirm the diagnosis, typically revealing microvascular thrombosis, endothelial damage, and perivascular inflammation. Imaging studies, such as Doppler ultrasound, can further assess vascular involvement and identify thrombosis. In some cases, advanced imaging such as MRI or CT may be necessary to evaluate the extent of systemic involvement. These diagnostic tools are critical as purpura fulminans must be differentiated from other conditions with similar presentations, including warfarin-induced skin necrosis, catastrophic antiphospholipid syndrome, cryoglobulinemic vasculitis, and heparin-induced thrombocytopenia [6].

Diagnosing purpura fulminans in critically ill patients presents unique challenges. The rapid clinical progression and overlapping symptoms with other severe conditions– such as sepsis, meningococcemia, or other coagulopathies– further complicate the diagnostic process [7]. A review and two case reports by Nolan et al. highlight the barriers to diagnosing PF, particularly due to the overlap of symptoms like high fever, chills, headache, and other systemic inflammatory responses [7]. It is imperative that healthcare professionals maintain a high index of suspicion, using a combination of clinical judgment, laboratory findings, and imaging to make a timely and accurate diagnosis [8].

## 2.2. Pathophysiological Mechanisms

### *2.2.1. Innate Immune Response*

The pathophysiology of purpura fulminans involves a complex interplay of thromboinflammation, with the innate immune response being a primary driver of disease progression. When exposed to infectious agents or injury, the innate immune response is activated, involving cells such as macrophages, neutrophils, and dendritic cells. These cells release pro-inflammatory cytokines, which act as amplifiers of the inflammatory response and upregulate tissue factor, initiating the coagulation pathway [9]. While this response is typically protective, aiming to contain infections and initiate tissue repair, it becomes maladaptive in PF. The dysregulation leads to excessive inflammation and formation of microvascular thrombi, a hallmark of the disease that contributes to its rapid progression and severity [10, 11]. Pro-inflammatory cytokines released during this dysregulated response drive further immune cell recruitment and tissue factor production. This creates a feedback loop that perpetuates the inflammatory and thrombotic processes.

Tissue factor on the surface of endothelial cells and monocytes further accelerates thrombin generation and subsequent fibrin deposition, fueling the coagulation process [12]. This cyclical interaction between inflammation and coagulation is a defining feature of PF and underlies the systemic and localized thrombosis observed in patients [13]. Moreover, recent research has highlighted the critical role of toll-like receptors (TLRs), which detect microbial products and initiate immune signaling in both innate and adaptive immunity [14]. The activation of TLRs not only propagates inflammatory signaling but also offers potential therapeutic targets for modulating the immune system without compromising infection control, presenting a new avenue for managing purpura fulminans.

### *2.2.2. Endothelial Dysfunction*

Endothelial dysfunction plays a critical role in the development of microvascular thrombosis and inflammation seen in purpura fulminans. Under normal physiological conditions, the endothelium regulates vascular homeostasis by controlling blood flow, modulating coagulation, and maintaining immune cell trafficking. However, in PF, endothelial cells become damaged and pro-thrombotic due to persistent exposure to inflammatory mediators and microbial toxins. This dysfunction is characterized by the upregulation of adhesion molecules such as ICAM-1 and VCAM-1, which promote leukocyte adhesion and transmigration into the vascular wall, exacerbating the local inflammatory response [15]. This process is triggered by lipopolysaccharide (LPS) and non-LPS components from *Neisseria meningitidis*, further driving endothelial activation.

As endothelial cells become activated, they release von Willebrand factor (vWF) andexpression tissue factor, both of which are critical in promoting coagulation. The breakdown of the endothelial barrier permits the extravasation of inflammatory cells and plasma proteins, leading to tissue damage and necrosis. This is compounded by a reduction in nitric oxide (NO) production, a molecule that typically inhibits platelet aggregation and leukocyte

adhesion. The decreased levels of NO create an environment conducive to thrombosis and inflammation, exacerbating the clinical presentation of PF [16]. Similar mechanisms of endothelial injury are observed in other thromboinflammitory conditions, such as SARS-CoV-2 infection, where complement-mediated vascular damage plays a central role in disease progression [16]. Understanding the molecular drivers of endothelial dysfunction has led to the identification of potential therapeutic targets. For instance, inflammatory cytokines and oxidative stress have been implicated in endothelial activation, suggesting that antioxidants and anti-inflammatory agents may help restore endothelial function [16]. Additionally, therapies aimed at enhancing endothelial cell survival and repair, including the use of endothelial progenitor cells, are under investigation. These strategies underscore the critical importance of maintaining endothelial integrity in preventing the thromboinflammitory sequelae of purpura fulminans and could pave the way for novel therapeutic approaches to mitigate endothelial damage in this severe condition.

### *2.2.3. Dysregulated Coagulation Pathways*

Dysregulated coagulation is a hallmark of purpura fulminans, characterized by an imbalance between pro-coagulant and anticoagulant forces that leads to extensive microvascular thrombosis [6]. This imbalance is largely driven by the overexpression of tissue factor, which initiates the extrinsic coagulation pathway and leads to extensive thrombin generation. In PF, increased tissue factor expression on endothelial cells and monocytes exacerbates thrombin production, converting fibrinogen to fibrin while activating protease-activated receptors (PARs) to amplifying inflammation [17]. The impairment of natural anticoagulant pathways, including antithrombin, protein C, and protein S, further contributes to unchecked thrombin activity and widespread fibrin deposition in the microvasculature [18]. Protein C, in particular, plays a critical role in both anticoagulation and anti-inflammation. Its dysfunction in PF significantly reduces its protective effects. A notable study by Majid et al. demonstrated that impairment of the protein C pathway leads to widespread fibrin deposition and uncontrolled thrombin activity, emphasizing the critical role of this pathway in the disease's progression [19]. The loss of protein C's anti-inflammatory functions further contributes to the severity of PF, as the unchecked coagulation cascade intensifies tissue damage and necrosis.

Recent research has provided further insight into the molecular mechanisms driving these dysregulated pathways. For instance, inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) downregulate thrombomodulin and the endothelial protein C receptor, further impairing the protein C pathway [20, 21, 22]. This downregulation perpetuates the procoagulant state by reducing the anticoagulant and anti-inflammatory functions of protein C, worsening disease outcomes. Additionally, the role of extracellular vesicles in transporting tissue factor and other pro-coagulant molecules to distant sites has been identified as a key factor in systemic thrombosis. Targeting these pathways with therapies such as recombinant protein C or tissue factor inhibitors may help restore coagulation balance in PF. Zifkos et al. further highlight the contribution of platelet-derived extracellular vesicles in supporting thrombin generation, particularly in procoagulant conditions, indicating that targeting these vesicles could mitigate the extensive clot formation in PF [23]. Inhibiting these pathways could offer a viable approach for addressing the underlying thromboinflammitory mechanisms of purpura fulminans, where disseminated intravascular coagulation remains a significant clinical challenge.

### *2.2.4. Complement Activation*

Complement activation is another critical player in the thromboinflammatory cascade of purpura fulminans. This system, integral to the innate immune response, is activated through classical, lectin, and alternative pathways, resulting in the production of anaphylatoxins (C3a, C5a) and the formation of the membrane attack complex (MAC). These complement components enhance inflammation, recruit and activate leukocytes, and increase endothelial permeability. Notably, anaphylatoxins serve as potent chemoattractants for neutrophils and other immune cells, further exacerbating inflammatory conditions. Evidence of complement activation in PF is underscored by studies reporting elevated levels of complement activation products in affected patients. These products not only amplify the inflammatory response but also contribute to a prothrombotic state by promoting endothelial cell activation and damage. For instance, Bendapudi et al. identified an enrichment of rare variants in the complement system among PF patients, which correlated with the severe thrombotic and inflammatory responses observed [24]. The formation of the MAC on endothelial cells can induce cell lysis and increase vascular permeability, thereby

exacerbating tissue injury. This interplay between complement activation, inflammation, and coagulation establishes a vicious cycle that drives the progression of purpura fulminans.

Insights into the mechanisms of complement activation have prompted investigations into complement inhibitors as potential therapeutic options. Eculizumab, a monoclonal antibody targeting C5, has demonstrated efficacy in mitigating the severity of complement-mediated diseases [25]. Although research on eculizumab's application in PF remains limited, identifying potential targets within the complement cascade suggests that monoclonal antibodies could represent viable treatment modalities for this condition. Ongoing research aims to uncover additional complement targets and develop inhibitors that selectively block the detrimental effects of complement activation while preserving its protective functions. These therapeutic approaches aim to interrupt the cycle of inflammation and thrombosis in purpura fulminans, offering renewed hope for affected patients.

#### *2.2.5. Neutrophil Extracellular Traps*

Neutrophil extracellular traps (NETs) have emerged as critical contributors to the pathophysiology of purpura fulminans [26]. These web-like structures, composed of decondensed chromatin and antimicrobial proteins, are released by neutrophils in response to infection or inflammation. While NETs play a protective role by trapping and neutralizing pathogens, excessive NET formation can lead to significant tissue damage and thrombosis [26]. In PF, this excessive formation is linked to endothelial injury, providing a scaffold for platelet adhesion and aggregation, thereby facilitating clot formation. This mechanism underpins the development of purpuric skin lesions and DIC seen in this condition. The persistence of NET-driven thrombosis can intensify the inflammatory response, creating a self-perpetuating cycle of endothelial injury, clot formation, and organ dysfunction.

NETs formation is triggered by stimuli, including microbial products, inflammatory cytokines, and activated platelets. Once released, NETs can trap not only pathogens but also red blood cells, platelets, and coagulation factors, creating a pro-thrombotic environment. Components of NETs, including histones and neutrophil elastase, possess both antimicrobial and cytotoxic properties. These molecules can disrupt cell membranes, aggravating endothelial cells and exacerbating inflammation [27]. Histones, particularly H2A, have been shown to effectively combat pathogens like *E. coli* and *Staphylococcus* species, while simultaneously contributing to cytotoxicity [27]. Elastase, another key component of NETs, further exacerbates endothelial injury, highlighting the dual role of NETs in both antimicrobial defense and promoting thrombosis.

While the dual role of NETs in antimicrobial defense and thrombosis underscores their complex function, it also highlights the risks associated with excessive NET formation, particularly in conditions like PF where their harmful effects are pronounced. The harmful effects of excessive NET formation in PF emphasize the potential of targeting NETs as a therapeutic strategy. Research into inhibitors of NETosis, such as DNase, shows promise in degrading NETs and reducing their inflammatory impact, without compromising pathogen clearance. Understanding the signaling pathways that trigger excessive NET formation may lead to the development of more refined interventions, offering a balance between modulating the immune response and preserving antimicrobial defense.

### 2.3. Current Treatment Strategies

The management of purpura fulminans centers on addressing the underlying cause, controlling the thromboinflammatory cascade, and preventing tissue damage. A cornerstone of treatment is anticoagulation, which aims to prevent further thrombus formation. Heparin and low molecular weight heparin (LMWH) are commonly used, with heparin inhibiting thrombin and LMWH inhibiting factor Xa. However, anticoagulation presents a significant challenge due to the associated risk of bleeding, especially in critically ill patients. Careful monitoring and dose adjustment are crucial to balance the prevention of thrombosis with minimizing bleeding complications. Additionally, the timing of anticoagulation initiation is crucial [28]. Studies have shown that early initiation of anticoagulation significantly reduces mortality, highlighting the importance of timely treatment.

Managing infections that precipitate purpura fulminans is equally critical. Sepsis is a common trigger, necessitating prompt antibiotic or antiviral therapy. Broad-spectrum antibiotics are typically initiated empirically and then tailored once the specific pathogen is identified. In cases

of PF linked to meningococcemia rapid antimicrobial therapy is crucial due to the potent inflammatory response triggered by meningococcal lipooligosaccharide (LOS), which is significantly more inflammatory than the lipopolysaccharide (LPS) from other bacteria like *E. coli* [29]. This increased potency highlights the heightened inflammatory and thrombotic response induced by meningococcal infections, explaining why PF associated with meningococcemia can progress so rapidly and severely. Effective management of such infections is pivotal in mitigating the systemic inflammatory response and improving patient outcomes. Early identification and aggressive management of infectious sources are essential to prevent further progression of purpura fulminans.

Immunomodulatory therapies such as intravenous immunoglobulin (IVIG) and corticosteroids are also utilized in the treatment of purpura fulminans. IVIG is thought to modulate immune responses by neutralizing antibodies and inhibiting cytokine release, proving particularly useful in autoimmune or idiopathic cases [30]. It has demonstrated success in rapidly reducing inflammation and resolving symptoms in conditions like Kawasaki disease [30]. A case report by Ghosh et al. discusses how IVIG has been anecdotally used to neutralize exotoxins in PF, highlighting the need for further research to clarify supporting the notion that long-term outcomes and optimal dosing regimens for these therapies are still unclear and require further study [31]. This supports the notion that while IVIG can be beneficial, its precise role in managing purpura fulminans is not yet fully understood.

Alternatively, corticosteroids are potent anti-inflammatory agents that reduce immune-mediated damage and inflammation. Their use must be carefully balanced, as they carry risks such as immunosuppression and increased infection susceptibility. The decision to use IVIG, corticosteroids, or both depends on the underlying cause, with IVIG showing efficacy in immune-mediated PF and corticosteroids more commonly used to dampen severe inflammatory responses [32]. Although these therapies have shown efficacy, their application remains variable and should be tailored to the specific etiology and patient presentation. Lastly, plasmapheresis, also known as therapeutic plasma exchange, offers an additional treatment option by removing pathogenic antibodies, immune complexes, and inflammatory mediators from circulation. This therapeutic approach has been used in both sepsis-related and autoimmune forms of PF, particularly when conventional therapies such as anticoagulation or immunosuppression fail to adequately control the coagulation cascade or inflammatory response. In cases involving antiphospholipid syndrome or post-infectious autoimmune mechanisms, plasmapheresis is often combined with immunosuppressive agents like corticosteroids to achieve better outcomes [33]. For example, in PF secondary to autoimmune clearance of protein S, plasmapheresis may be used alongside fresh frozen plasma and immunosuppression to restore adequate coagulation [5]. While further studies are needed to refine the exact indications, frequency, and duration of plasmapheresis in various clinical scenarios, its role in managing severe or refractory purpura fulminans remains pivotal. It also has the added benefit of preventing fluid overload in patients requiring large-volume resuscitation, adding to its value in critical care settings.

Case studies emphasize the importance of a multidisciplinary approach to the treatment of purpura fulminans, which often involves infectious disease specialists, hematologists, critical care teams, and occasionally, rheumatologists. For instance, in cases of meningococcemia-associated PF, early recognition and aggressive antibiotic therapy, alongside timely initiation of anticoagulation have been linked to improved outcomes [6]. In autoimmune-related PF, the combination of IVIG, platelet transfusion, and corticosteroids, has shown favorable responses, particularly in cases complicated by immune thrombocytopenia [34]. These cases underlie the necessity of individualized treatment plans tailored to the underlying etiology and patient response, as well as the critical importance of early diagnosis and continuous monitoring to optimize patient outcomes. Timely intervention can prevent rapid progression and reduce risk of long-term complications, which is crucial in this life-threatening condition.

### 2.4. Challenges and Controversies in Management

The successful management of purpura fulminans requires rapid implementation of supportive care and prompt recognition of the underlying cause. However, limited evidence supporting clinical decision-making, coupled with a lack of standardized treatment protocols, contributes to the variability in patient outcomes. Given the rarity of PF, many therapeutic guidelines draw from protocols for DIC, which

may not always address the complexities of PF. Additionally, the challenges of balancing pro-coagulant and anticoagulant therapies highlight the need for more disease-specific approaches to improve patient outcomes. The continued development of therapies for this condition focuses on replacing depleted anticoagulants like protein C and antithrombin, which are critical to managing the coagulopathy that characterizes the disease.

The use of anticoagulation therapy in purpura fulminans remains a subject of controversy, particularly in patients with concurrent DIC. While anticoagulants like heparin are essential for managing large vessel venous thrombosis, the heightened risk of bleeding complicates their use [35]. Heparin's efficiency is further challenged by the inflammation associated with PF, which can bind and inactivate the drug, necessitating higher doses for therapeutic effect. Careful surveillance of anti-Xa and partial thromboplastin time is recommended to optimize heparin therapy [6]. Despite these challenges, studies indicate that combining heparin with fresh frozen plasma (FFP) may mitigate heparin resistance and reduce bleeding risks. For instance, Chalmers et al.recommend using FFP alongside heparin to mitigate potential complications [5]. This combination is crucial, as FFP helps replenish deficient coagulation factors, which allows for more effective anticoagulation. For instance, a protocol developed by Branson et al., in which FFP administration preceded heparin treatment by seven days, demonstrated efficacy in treating a 5-year-old with PF [36]. This protocol evolved from a previous case of heparin-resistant PF, where FFP played a critical role in managing coagulopathy. Similar outcomes were observed by Gurgey et al., who initiated heparin therapy immediately following a single dose of FFP in 10 patients, suggesting that early FFP administration may prime the coagulation system and enhance subsequent heparin efficacy [37]. Further illustrating this approach, Pombar et al. reported favorable outcomes in an 8-year-old boy, where immediate initiation of FFP followed by heparin for 72 hours, and subsequent enoxaparin therapy for several months, resulted in recovery [38]. This highlights the utility of sequential FFP and anticoagulation in managing pediatric PF, underscoring the need for standardized protocols. These case reports suggest that early administration of FFP primes the coagulation system, enhancing heparin's efficiency while reducing resistance and bleeding risks. Further studies are needed to assess the optimal timing and combination of these therapies.

Patients with DIC and purpura fulminans often exhibit low levels of protein C, a key factor in the disease's pathophysiology. Studies have shown that in cases of acquired protein C deficiency secondary to meningococcal infection, protein C levels directly correlate with symptom severity [39]. This underscores the importance of monitoring protein C levels as a prognostic marker, guiding the urgency of therapeutic interventions to prevent disease progression. Activated protein C showed therapeutic promise in the 1990s but was withdrawn after the PROWESS-SHOCK trial failed to show significant differences in mortality compared to placebo [6]. Despite this, there is growing evidence supporting the use of protein C concentrate, the inactive form that activates in vivo, as a viable therapy. Protein C replacement has shown efficacy in reducing morbidity and improving coagulation parameters in severe meningococcal septicemia [5, 39]. Although protein C concentrate has not yet been approved for sepsis-associated purpura fulminans, it is approved for managing congenital protein C deficiency, highlighting its therapeutic potential.

In congenital protein C deficiency, purpura fulminans can manifest within hours of birth, and immediate replacement of protein C is paramount to survival. FFP is often used as a temporary solution until protein C concentrate becomes available. Dinarvand et al. recommended an initial dose of 100 units/kg, followed by 50 units/kg every 6–12 hours for active PF [40]. This dosing regimen ensures consistent and adequate replacement to manage the coagulopathy associated with PF. A case series by Manco-Johnson et al. involving 25 patients with congenital protein C deficiency demonstrated good outcomes with doses of 60 units/kg daily during acute episodes [41]. While protein C concentrate is currently limited to congenital cases, its potential benefit in acquired deficiency suggests that expanding its approval could provide a critical therapeutic option for managing purpura fulminans.

Antithrombin depletion also contributes to the coagulopathy in purpura fulminans, and replacement therapy has shown potential benefits. In a case series by Munteanu et al. three patients with severe PF and DIC demonstrated positive outcomes after antithrombin replacement, despite low levels of protein C [42]. These patients were treated with early plasma exchange followed by antithrombin replacement,

avoiding heparin, which can counteract antithrombin's anti-inflammatory properties. Similarly, a study by Fourrier et al. showed successful outcomes in five patients with meningococcemia-associated PF treated with high doses of antithrombin [43]. These studies suggest that antithrombin may compensate for protein C deficiencies in managing the coagulopathy of purpura fulminans, though further research is needed to clarify its role in treatment protocols. Based on these findings, the Japanese Association for Acute Medicine (JAAM) has included antithrombin supplementation in their guidelines for managing sepsis-associated DIC [44].

Despite evidence supporting the therapeutic potential of antithrombin, its use in purpura fulminans remains controversial due to concerns for increased bleeding risk. A double-blind, placebo-controlled trial by Warren et al. found that while high doses of antithrombin reduced mortality in septic patients, it also significantly raised the risk of hemorrhagic complications, especially when used with heparin [45]. A follow-up study by Iba et al. showed improved outcomes of sepsis-associated DIC with 3,000 IU/day of antithrombin without heparin, reducing bleeding risks compared to lower doses [46]. These findings underscore the need for careful consideration of bleeding risks in antithrombin therapy, particularly when combined with heparin, and suggest that plasma exchange timing could play a pivotal role in reducing complications. As research on antithrombin therapy in DIC and purpura fulminans progresses, continued research will be critical in identifying its optimal use and incorporation into standardized treatment protocols.

### 2.5. Emerging Therapeutic Avenues

Advances in understanding the pathophysiological mechanisms of purpura fulminans have led to the exploration of novel therapeutic strategies aimed at targeting the thromboinflammatory processes involved. Toll-like receptor (TLR) inhibitors,such as TAK-242 (a TLR4 inhibitor), are emerging as potential therapeutic agents by reducing the excessive inflammatory responses mediated by TLR activation [47]. Inhibiting this pathway could potentially alleviate the severity of PF by limiting innate immune overactivation. Another promising approach focuses on modulating NETs, which contribute to both thrombosis and tissue damage. Strategies such as the use of DNase to degrade extracellular DNA are being explored for their therapeutic potential [48]. This approach aims to reduce the thrombotic and inflammatory burden by breaking down the NETs that exacerbate the condition.

Complement inhibition has also shown promise, particularly with agents like eculizumab that block complement activation. By doing so, these therapies can reduce endothelial damage and control the associated thrombosis and inflammation that characterize PF [49]. Alternatively, cytokines like IL-1 and TNF-alpha are key modulators in the inflammatory cascade in PF. Targeted therapies, such as anakinra (an IL-1 receptor antagonist) and infliximab (a TNF-alpha inhibitor), aim to interrupt these pathways and alleviate both inflammation and thrombosis, potentially improving patient outcomes [50]. Together, these therapies emphasize the importance of targeting multiple pathways involved in the inflammatory and thrombotic processes of purpura fulminans.

In addition, antithrombotic agents with anti-inflammatory properties, such as direct oral anticoagulants (DOACs), are being explored for their potential to treat purpura fulminans, given their ability to inhibit thrombin and factor Xa while reducing inflammation [51]. However, more research is warranted to explore their efficacy and safety in this context. Further ongoing studies are investigating agents that stabilize endothelial function and therapies targeting specific coagulation pathways. Continued research is essential to translate these findings into clinical practice, and future trials must focus on the development of standardized protocols. Personalized medicine, incorporating genetic and clinical profiles, will likely play a crucial role in optimizing therapeutic outcomes for purpura fulminans.

### 2.6. Future Directions and Research

Although rare, purpura fulminans remains a formidable clinical challenge, largely due to the lack of high-quality evidence guiding its management. Current therapeutic strategies are primarily supported by case reports and small case series, limiting their generalizability. This reliance introduces potential publication bias, as successful treatments are more likely to be reported and published. Conducting placebo-controlled trials, while ideal, is impractical in PF due to its severe and rapidly progressive clinical nature, making untreated control groups ethically untenable. Nonetheless, future large-scale observational studies are urgently needed to provide information regarding efficacy, safety, and dosing to develop a reliable protocol with

sufficient evidence to evaluate treatment efficacy, safety, and optimal dosing. The formation of complex interdisciplinary groups accelerates scientific development and improves patient outcomes by bridging the gap between scientific research and clinical practice [52]. The collaboration between basic scientists, clinicians, and industry partners is critical to accelerate the development of new therapies.

One promising avenue for future research lies in the identification of purpura fulminans-specific biomarkers. For example,a study by He et al. identified 27 serum proteins uniquely expressed in patients with PF, offering potential targets for early diagnosis and therapeutic intervention [53]. Further exploration of these biomarkers could enhance our understanding of the molecular mechanism underlying PF and inform the developments of novel treatments. Additionally, genetic studies are essential to uncover predispositions to PF, particularly in cases linked to congenital deficiencies in protein C [40]. Expanding our understanding of the genetic landscape in purpura fulminans may pave the way for personalized medicine approaches, optimizing therapeutic strategies for individualized patients based on their genetic profiles.

The skin microbiome also represents a novel research frontier in PF. Given the role of infections as a catalyst for PF, investigating how variations in the microbiome may influence susceptibility to PF could yield important insight. Furthermore, exploring how microbial diversity or lack thereof, affects disease progression may offer new preventive strategies. Lastly, integrating personalized medicine approaches, such as tailoring therapies based on biomarkers, genetic predispositions, and microbial profiles, will likely be critical in improving patient outcomes in the future. The development of these precision medicine strategies, coupled with ongoing research into the thromboinflammitory mechanisms of purpura fulminans, will be vital in establishing more effective, targeted treatments.

## 3. Conclusion

Purpura fulminans is a rare, life-threatening condition marked by a rapid and severe thromboinflammatory response, which can lead to significant morbidity and mortality. Despite advances in understanding its pathophysiology, management remains challenging due to the lack of standardized treatment protocols and robust clinical trials. Current treatment strategies, while promising, are supported mainly by limited case reports and series, underscoring the need for more comprehensive research. Emerging therapeutic avenues, targeting complement inhibitors, toll-like receptor antagonists, and antithrombotic agents, offer hope but require further investigation to assess their efficacy and safety in PF patients. Future research efforts should focus on large-scale studies to provide robust data on treatment efficacy, safety, and dosing. The identification of PF-specific biomarkers, genetic predispositions, and insights into the skin's microbiome could offer new avenues for early diagnosis and targeted therapies. Additionally, interdisciplinary collaboration between scientists, clinicians, and industry partners will be crucial to accelerate the development of new treatments. Ultimately, the goal is to develop standardized, evidence-based treatment protocols that can improve survival rates and quality of life for patients affected by purpura fulminans.

## References

[1] Perera, T. B., & Murphy-Lavoie, H. M. (2023). Purpura Fulminans. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK532865/

[2] Waisman, D., Baenziger, O., & Gall, N. (2008). Hyperbaric oxygen therapy in newborn infants and pediatric patients. *Physiology and Medicine of Hyperbaric Oxygen Therapy*, 95–116. https://doi.org/10.1016/b978-1-4160-3406-3.50011-1

[3] Bhatti, U. F., Williams, A. M., Raghavendran, K., & Georgoff, P. E. (2019). Four-extremity amputation following disseminated intravascular coagulation and Purpura Fulminans. *BMJ Case Reports*, *12*(3). https://doi.org/10.1136/bcr-2018-228028

[4] Nasrullah, A., Javed, A., Tariq, U., Young, M., Moeen, Z., & Balaan, M. (2019). Purpura fulminans: A rare but fierce presentation of pneumococcal sepsis. *European Journal of Case Reports in Internal Medicine*, *7*(1). https://doi.org/10.12890/2019_001373

[5] Chalmers, E., Cooper, P., Forman, K., Grimley, C., Khair, K., Minford, A., Morgan, M., & Mumford, A. (2011). Purpura fulminans: Recognition, diagnosis and management. *Archives of Disease in Childhood*, *96*(11), 1066–1071. https://doi.org/10.1136/adc.2010.199919

[6] Colling, M. E., & Bendapudi, P. K. (2018). Purpura fulminans: Mechanism and management of dysregulated hemostasis. *Transfusion Medicine Reviews*, *32*(2), 69–76. https://doi.org/10.1016/j.tmrv.2017.10.001

[7] Nolan, J., & Sinclair, R. (2001). Review of Management of Purpura Fulminans and two case reports. *British Journal of Anaesthesia*, *86*(4), 581–586. https://doi.org/10.1093/bja/86.4.581

[8] Bollero, D., Stella, M., Gangemi, E., Spaziante, L., Nuzzo, J., Sigaudo, G., & Enrichens, F. (2010). Purpura Fulminans in Meningococcal Septicaemia in an Adult: A Case Report. *Annals of Burns and Fire Disasters*, *23*(1), 43–47.

[9] Mandel, J., Casari, M., Stepanyan, M., Martyanov, A., & Deppermann, C. (2022). Beyond hemostasis: Platelet innate immune interactions and thromboinflammation. *International Journal of Molecular Sciences*, *23*(7), 3868. https://doi.org/10.3390/ijms23073868

[10] Levi, M., & Sivapalaratnam, S. (2018). Disseminated intravascular coagulation: An update on pathogenesis and diagnosis. *Expert Review of Hematology*, *11*(8), 663–672. https://doi.org/10.1080/17474086.2018.1500173

[11] Mahdaviani, A., Fallahpour, M., Seif, F., Alyasin, S., Abolhassani, H., Bousfiha, A., Barbouche, M.-R., & Olbrich, P. (2021). Defects in intrinsic and innate immunity. *Inborn Errors of Immunity*, 219–243. https://doi.org/10.1016/b978-0-12-821028-4.00002-6

[12] Neubauer, K., & Zieger, B. (2021). Endothelial cells and coagulation. *Cell and Tissue Research*, *387*(3), 391–398. https://doi.org/10.1007/s00441-021-03471-2

[13] Asilian, A., Iraji, F., Fatemi Naeini, F., Faghihi, G., Mokhtari, F., Mohaghegh, F., Saber, M., & Mozafarpoor, S. (2021). Purpura and microvascular occlusion. *Atlas of Dermatology, Dermatopathology and Venereology*, 421–437. https://doi.org/10.1007/978-3-319-53808-2_95

[14] Hug, H., Mohajeri, M., & La Fata, G. (2018). Toll-like receptors: Regulators of the immune response in the human gut. *Nutrients*, *10*(2), 203. https://doi.org/10.3390/nu10020203

[15] Dixon, G. L., Heyderman, R. S., Van Der Ley, P., & Klein, N. J. (2003). High-level endothelial E-selectin (CD62E) cell adhesion molecule expression by a lipopolysaccharide-deficient strain of Neisseria meningitidis despite poor activation of NF-κB transcription factor. *Clinical and Experimental Immunology*, *135*(1), 85–93. https://doi.org/10.1111/j.1365-2249.2004.02335.x

[16] Mondal, R., Lahiri, D., Deb, S., Bandyopadhyay, D., Shome, G., Sarkar, S., Paria, S. R., Thakurta, T. G., Singla, P., & Biswas, S. C. (2020). Covid-19: Are we dealing with a multisystem vasculopathy in disguise of a viral infection? *Journal of Thrombosis and Thrombolysis*, *50*(3), 567–579. https://doi.org/10.1007/s11239-020-02210-8

[17] Gando, S., Levi, M., & Toh, C.-H. (2016). Disseminated intravascular coagulation. *Nature Reviews Disease Primers*, *2*(1). https://doi.org/10.1038/nrdp.2016.37

[18] Edlich, R., Cross, C. L., Dahlstrom, J. J., & Long III, W. B. (2008). Modern concepts of the diagnosis and treatment of Purpura Fulminans. *Journal of Environmental Pathology, Toxicology and Oncology*, *27*(3), 191–196. https://doi.org/10.1615/jenvironpatholtoxicoloncol.v27.i3.30

[19] Majid, Z., Tahir, F., Ahmed, J., Bin Arif, T., & Haq, A. (2020). Protein C deficiency as a risk factor for stroke in young adults: A Review. *Cureus*. https://doi.org/10.7759/cureus.7472

[20] Eliwan, H., Omer, M., McKenna, E., Kelly, L. A., Nolan, B., Regan, I., & Molloy, E. J. (2022). Protein C pathway in paediatric and neonatal sepsis. *Frontiers in Pediatrics*, *9*. https://doi.org/10.3389/fped.2021.562495

[21] Pilard, M., Ollivier, E. L., Gourdou-Latyszenok, V., Couturaud, F., & Lemarié, C. A. (2022). Endothelial Cell Phenotype, a major determinant of venous thrombo-inflammation. *Frontiers in Cardiovascular Medicine*, *9*. https://doi.org/10.3389/fcvm.2022.864735

[22] Kwaifa, I. K., Bahari, H., Yong, Y. K., & Noor, S. M. (2020). Endothelial dysfunction in obesity-induced inflammation: Molecular mechanisms and clinical implications. *Biomolecules*, *10*(2), 291. https://doi.org/10.3390/biom10020291

[23] Zifkos, K., Dubois, C., & Schäfer, K. (2021). Extracellular vesicles and thrombosis: Update on the clinical and experimental evidence. *International Journal of Molecular Sciences*, *22*(17), 9317. https://doi.org/10.3390/ijms22179317

[24] Bendapudi, P., Ryu, J., Soylemez, O., Rouaisnel, B., Colling, M., Pasko, B., Robbins, A., Bouzinier, M., Tomczak, L., Ram, S., Toth-Petroczy, A., Krier, J., Fieg, E., Dzik, W., Hudspeth, J., Pozdnyakova, O., Nardi, V., Maas, R., & Losman, J.-A. (2020). Rare inherited defects of the complement system in Purpura Fulminans. *Blood*, *136*(Supplement 1), 35–36. https://doi.org/10.1182/blood-2020-138729

[25] Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019). Clinical promise of next-generation complement therapeutics. *Nature Reviews Drug Discovery*, *18*(9), 707–729. https://doi.org/10.1038/s41573-019-0031-6

[26] Mutua, V., & Gershwin, L. J. (2020). A review of neutrophil extracellular traps (nets) in disease: Potential anti-nets therapeutics. *Clinical Reviews in Allergy & Immunology*, *61*(2), 194–211. https://doi.org/10.1007/s12016-020-08804-7

[27] Delgado-Rizo, V., Martínez-Guzmán, M. A., Iñiguez-Gutierrez, L., García-Orozco, A.,

Alvarado-Navarro, A., & Fafutis-Morris, M. (2017). Neutrophil extracellular traps and its implications in inflammation: An overview. *Frontiers in Immunology*, *8*. https://doi.org/10.3389/fimmu.2017.00081

[28] Betrosian, A. P., Berlet, T., & Agarwal, B. (2006). Purpura fulminans in sepsis. *The American Journal of the Medical Sciences*, *332*(6), 339–345. https://doi.org/10.1097/00000441-200612000-00006

[29] Lécuyer, H., Borgel, D., Nassif, X., & Coureuil, M. (2017). Pathogenesis of meningococcal purpura fulminans. *Pathogens and Disease*. https://doi.org/10.1093/femspd/ftx027

[30] Gupta, M., Noel, G. J., Schaefer, M., Friedman, D., Bussel, J., & Johann-Liang, R. (2001). Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. *Journal of Clinical Immunology*, *21*(3), 193–199. https://doi.org/10.1023/a:1011039216251

[31] Ghosh, M., Sinha Ray, A., Song, M., Varney, J., Ghosh, S., Koirala, J., DeFrain, C., & Quarshie, C. (2016). Staphylococcus-associated Purpura Fulminans: Can we expect a better outcome with intravenous immunoglobulin? *Chest*, *149*(4). https://doi.org/10.1016/j.chest.2016.02.143

[32] Bierling, P., & Godeau, B. (2004). Intravenous immunoglobulin and autoimmune thrombocytopenic purpura: 22 years on. *Vox Sanguinis*, *86*(1), 8–14. https://doi.org/10.1111/j.0042-9007.2004.00391.x

[33] Croles, F. N., te Boekhorst, P. A. W., Leebeek, F. W. G., & Jansen, A. J. G. (2021). Therapeutic Plasma Exchange for anticoagulant-refractory antiphospholipid syndrome with severe ischemic and necrotic skin lesions: A case series. *Transfusion and Apheresis Science*, *60*(5), 103192. https://doi.org/10.1016/j.transci.2021.103192

[34] Theron, A., Dautremay, O., Boissier, E., Zerroukhi, A., Baleine, J., Moulis, L., Rodière, M., Schved, J.-F., Duraes, M., Kanouni, T., Cau-Diaz, I., Jeziorski, E., & Biron-Andreani, C. (2022). Idiopathic purpura fulminans associated with anti-protein s antibodies in children: A multicenter case series and systematic review. *Blood Advances*, *6*(2), 495–502. https://doi.org/10.1182/bloodadvances.2021005126

[35] Wada, H., Thachil, J., Di Nisio, M., Mathew, P., Kurosawa, S., Gando, S., Kim, H. k., Nielsen, J. d., Dempfle, C.-E., Levi, M., & Toh, C. (2013). Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines. *Journal of Thrombosis and Haemostasis*, *11*(4), 761–767. https://doi.org/10.1111/jth.12155

[36] Branson, H. E., & Katz, J. (1983). A structured approach to the management of purpura fulminans. *Journal of the National Medical Association*, *75*(8), 821–825.

[37] Gürgey, A., Aytac, S., Kanra, G., Secmeer, G., Ceyhan, M., & Altay, C. (2005). Outcome in children with Purpura Fulminans: Report on 16 patients. *American Journal of Hematology*, *80*(1), 20–25. https://doi.org/10.1002/ajh.20435

[38] Pombar, R. F., Tellería, R. L., Bianco, B., Del V Centeno, M., & Cervini, A. B. (2024). Postinfectious Purpura fulminans: A case report. *Archivos Argentinos de Pediatria*, *122*(4). https://doi.org/10.5546/aap.2023-10137.eng

[39] White, B., Livingstone, W., Murphy, C., Hodgson, A., Rafferty, M., & Smith, O. P. (2000). An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in Purpura Fulminans–Associated Meningococcemia. *Blood*, *96*(12), 3719–3724. https://doi.org/10.1182/blood.v96.12.3719.h8003719_3719_3724

[40] Dinarvand, P., & Moser, K. A. (2019). Protein C deficiency. *Archives of Pathology & Laboratory Medicine*, *143*(10), 1281–1285. https://doi.org/10.5858/arpa.2017-0403-rs

[41] Manco-Johnson, M., Hertfelder, H.-J., Kalfa, T. A., Broxson, E. H., Bomgaars, L., Shapiro, A. D., Jacqueline, D.-J., Ehrle, S., Finnerty, M., Gelmont, D., Yel, L., & Loghman-Adham, M. (2016). Treatment of patients with severe congenital protein C deficiency in a registry study of protein C concentrate (human). *Blood*, *128*(22), 2605–2605. https://doi.org/10.1182/blood.v128.22.2605.2605

[42] Munteanu, C., Bloodworth, L. L., & Korn, T. H. (2000). Antithrombin concentrate with plasma exchange in Purpura Fulminans. *Pediatric Critical Care Medicine*, *1*(1), 84–87. https://doi.org/10.1097/00130478-200007000-00016

[43] Fourrier, F., Lestavel, P., Chopin, C., Marey, A., Goudemand, J., Rime, A., & Mangalaboyi, J. (1990). Meningococcemia and purpura fulminans in adults: Acute deficiencies of proteins C and S and early treatment with Antithrombin III concentrates. *Intensive Care Medicine*, *16*(2), 121–124. https://doi.org/10.1007/bf02575306

[44] Wada, Hideo, Asakura, H., Okamoto, K., Iba, T., Uchiyama, T., Kawasugi, K., Koga, S., Mayumi, T., Koike, K., Gando, S., Kushimoto, S., Seki, Y., Madoiwa, S., Maruyama, I., & Yoshioka, A. (2010). Expert consensus for the treatment of disseminated intravascular coagulation in Japan.

*Thrombosis Research*, *125*(1), 6–11. https://doi.org/10.1016/j.thromres.2009.08.017

[45] Warren, B. L., Eid, A., Singer, P., Pillay, S. S., Carl, P., Novak, I., Chalupa, P., Atherstone, A., Pénzes, I., Kübler, A., Knaub, S., Keinecke, H.-O., Heinrichs, H., Schindel, F., Juers, M., Bone, R. C., & Opal, S. M., & KyberSept Trial Study Group (2001). High-dose antithrombin III in severe sepsis. *JAMA*, *286*(15), 1869-1878. https://doi.org/10.1001/jama.286.15.1869

[46] Iba, T., Saitoh, D., Wada, H., & Asakura, H. (2014). Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: A secondary survey. *Critical Care*, *18*(5). https://doi.org/10.1186/s13054-014-0497-x

[47] Duan, T., Du, Y., Xing, C., Wang, H. Y., & Wang, R.-F. (2022). Toll-like receptor signaling and its role in cell-mediated immunity. *Frontiers in Immunology*, *13*. https://doi.org/10.3389/fimmu.2022.812774

[48] Zhou, Y., Xu, Z., & Liu, Z. (2022). Impact of neutrophil extracellular traps on thrombosis formation: New Findings and Future Perspective. *Frontiers in Cellular and Infection Microbiology*, *12*. https://doi.org/10.3389/fcimb.2022.910908

[49] Cofiell, R., Kukreja, A., Bedard, K., Yan, Y., Mickle, A. P., Ogawa, M., Bedrosian, C. L., & Faas, S. J. (2015). Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. *Blood*, *125*(21), 3253–3262. https://doi.org/10.1182/blood-2014-09-600411

[50] Donnelly, R. P., Young, H. A., & Rosenberg, A. S. (2009). An overview of cytokines and cytokine antagonists as therapeutic agents. *Annals of the New York Academy of Sciences*, *1182*(1), 1–13. https://doi.org/10.1111/j.1749-6632.2009.05382.x

[51] Russo, V., Falco, L., Tessitore, V., Mauriello, A., Catapano, D., Napolitano, N., Tariq, M., Caturano, A., Ciccarelli, G., D'Andrea, A., & Giordano, A. (2023). Anti-inflammatory and anticancer effects of anticoagulant therapy in patients with malignancy. *Life*, *13*(9), 1888. https://doi.org/10.3390/life13091888

[52] Acedo, P., & Russo, F. P. (2019). Young GI Angle: A young point of view on Translational Medicine. *United European Gastroenterology Journal*, *7*(6), 864–865. https://doi.org/10.1177/2050640619857963

[53] He, T., Hu, J., Han, J., Zhang, D., Jiang, X., Chen, B., & Huang, Y. (2014). Identification of differentially expressed serum proteins in infectious purpura fulminans. *Disease Markers*, *2014*, 1–8. https://doi.org/10.1155/2014/698383

**Citation:** *Kelly Frasier et al. Targeting Thromboinflammation in Purpura Fulminans: Novel Therapeutic Avenues in Critical Care. ARC Journal of Dermatology. 2025; 8(2):36-47. DOI: https://doi.org/10.20431/2456-0022.0802004*